ELAN — Elanco Animal Health Incorporated price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $25.85
- YTD price return
- +14.23%
- YTD total return
- +14.23%
- Market cap
- 12.9B
- Enterprise value
- 16.5B
- Shares outstanding
- 499.8M
- 52W low
- $19.40
- 52W high
- $27.98
- From 52W high
- -7.61%
- From 52W low
- +33.25%
- 52W range
- 75%$19.40–$27.98
- Beta
- 1.67
Volume
- Rel volume
- 0.74×
- 30D volume
- 5.2M
- 30D $ vol
- 124.7M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- +$836K
- Insider net 1Y
- +$1.6M
Form 4 transactions by trade date, as filed; latest on file 2026-10-15.
Fundamentals
- Sales (ttm)
- 5.1B
- Sales/share
- $10.30
- EPS (ttm)
- -$0.29
- FCF (ttm)
- 408M
- FCF/share
- $0.82
- Book value/share
- $13.26
- Net margin
- -2.86%
- ROE
- -2.22%
- ROA
- -1.10%
- Debt / equity
- 0.55×
- Current ratio
- 2.09
Growth (CAGR, ttm) · 10Y
- Sales
- +12.14%+5.64%+1.46%+6.01%
- FCF
- +10.88%+51.18%+4.98%+25.21%
- Shares
- +0.60%+0.47%+1.11%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +11.48%+5.14%+0.35%n/a
- FCF/share
- +10.22%+50.42%+3.77%n/a
- Book value/share
- -2.38%+2.13%-3.97%n/a
- Price
- +20.70%+29.79%-4.15%n/a
- Total return
- +20.70%+29.79%-4.15%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -87.9×
- Fwd P/E
- 20.7×
- P/S (ttm)
- 2.5×
- P/B (mrq)
- 1.9×
- P/FCF (ttm)
- 31.7×
- EV/Sales (ttm)
- 3.2×
- FCF yield (ttm)
- 3.16%
- Buyback yield (realized, 1y)
- -0.60%
- Shareholder yield (realized, 1y)
- -0.60%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 53rd
- P/B
- 80th
- P/FCF
- 59th
Bar = where today’s multiple sits in ELAN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Net income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY +22.8%TTM: operating cash flow $614M, capex −$206M
Q3 2026: operating cash flow $216M, capex −$60M
Shares (diluted)
5Y +12.5%5Y +12.5%YoY +2.0%Gross profit
5Y CAGR +10.1%5Y CAGR +10.1%YoY +18.6%About Elanco Animal Health#
Data provided bySource: Twelve DataElanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock. The company serves veterinarians, pet owners, farmers, and producers across a wide range of species, including dogs, cats, cattle, poultry, swine, and sheep. Elanco Animal Health Incorporated also offers products used in food-animal health and production settings, supporting disease prevention and animal wellbeing in everyday care and commercial agriculture. Headquartered in Indianapolis, Indiana, Elanco Animal Health Incorporated operates as a diversified participant in the global animal health market, with a broad product mix spanning companion animal and farm animal care.
Indianapolis, IN·9,400 employees·Drug Manufacturers - Specialty & Generic·elanco.com·As of Oct 28, 2026
Recent filings#
- Nov 6Earnings · Earnings release — EPS $0.27 vs $0.20 est. (+35.0%); revenue $1.26B (+11% y/y) 8.7%
- Aug 20Insider buy · Kurzius Lawrence Erik (Director) bought 40,000 shares for $936K at $23.40
- Aug 18Insider buy · O'Neill Shiv (GC AND CORP SEC) bought 3,998 shares for $94K at $23.58
- Aug 12Insider buy · Harrington Michael J (Director) bought 5,000 shares for $109K at $21.82
- Aug 7Insider buy · Herendeen Paul (Director) bought 10,000 shares for $237K at $23.69
ETFs holding ELAN#
19 of the 193 ETFs ChartRow carries live hold ELAN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| VBR | Vanguard Small-Cap Value ETF | 0.3% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
